MDLNMedline Inc.
Is the price fair?
In line with its sector. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What MDLN's price assumes
Medline Inc. has no trailing P/E on file, so the price is measured against sales instead: 1.58× revenue.
Price / sales · no trailing P/E on file: measured against sales instead
- Price / book
- 4.17
Price / book · today's price, fiscal year to Dec 31, 2025
- EV / sales
- 1.95
EV / sales
Details›
- Price / booktoday's price, fiscal year to Dec 31, 2025
- 4.17
- EV / EBITtoday's price, fiscal year to Dec 31, 2025
- 25.1
- EV / salestoday's price, fiscal year to Dec 31, 2025
- 1.95
- Market capitalisation1.31 billion shares, counted Aug 3, 2026
- $44.8B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Instruments & Supplies
The closest names by size in the same industry